Abstract | BACKGROUND: CASE PRESENTATION: CONCLUSIONS: This report highlights the importance of detailed donor assessment, close follow-up and timely treatment of unexpected donor-transmitted malignancy. Although pathology is the most important evidence for the exclusion of donors for malignant potential, it should be combined with tumor type, tumor size and speed of growth. Organs from donors with malignant potential should be discarded. Allograft nephrectomy should be considered after confirmation of renal-allograft synovial sarcoma. Anlotinib for synovial sarcoma seems to be effective and well tolerated during long-term follow-up.
|
Authors | Jian Zhang, Yang Yang, Ye Tian, Ruifang Xu, Jun Lin |
Journal | Diagnostic pathology
(Diagn Pathol)
Vol. 16
Issue 1
Pg. 118
(Dec 14 2021)
ISSN: 1746-1596 [Electronic] England |
PMID | 34906181
(Publication Type: Case Reports, Journal Article)
|
Copyright | © 2021. The Author(s). |
Topics |
- Humans
- Kidney Transplantation
(adverse effects)
- Nephrectomy
- Sarcoma, Synovial
(diagnosis)
- Tissue Donors
- Transplant Recipients
|